CStone

Public 2616.HK · China

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
Approved in the EU
Next date
CS2009, First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan)
Drugs
5
in active trials · 10 in all
Trials
6 active
28 since 2021

Drugs5

DrugHow it worksPartnerStageNext dateDetails
PD-L1 antibody
Approved in the EU Dec 2029Phase 3 trial completes
Monoclonal antibody
Phase 3 —
PD-1/VEGF/CTLA-4 trispecific antibody
Phase 1/2 Dec 2026First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan)
CS5006not checked
—
Phase 1/2 Jul 2029Phase 1/2 trial completes
—
Phase 1 Jan 2028Phase 1 trial completes

About

No active trial
CS1002, CS3002, CS3005, CS3006, CS5001
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev

Follow CStone

Following is part of Solo: you see every change to CStone the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in